EyeGate Pharmaceuticals (EYEG) 10-Q 3 Aug 18 2018 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 01, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Entity Registrant Name	EYEGATE PHARMACEUTICALS INC
Entity Central Index Key	1,372,514
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	EYEG
Entity Common Stock, Shares Outstanding		43,439,130

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current Assets:
Cash and Cash Equivalents	$ 12,604,803	$ 7,806,029
Prepaid Expenses and Other Current Assets	614,845	629,591
Current Portion of Refundable Tax Credit Receivable	14,988	23,685
Total Current Assets	13,234,636	8,459,305
Property and Equipment, Net	39,819	55,751
Restricted Cash	45,000	45,000
Goodwill and In-Process R&D	5,438,210	5,438,210
Other Assets	307,126	307,126
Total Assets	19,064,791	14,305,392
Current Liabilities:
Accounts Payable	356,025	706,089
Accrued Expenses	1,041,672	1,813,847
Deferred Revenue	2,723,000	12,313,600
Total Current Liabilities	4,120,697	14,833,536
Non-Current Liabilities:
Contingent Consideration	1,210,000	1,210,000
Deferred Tax Liability	183,923	183,923
Long-Term Portion of Capital Lease Obligation	1,712	4,855
Total Non-Current Liabilities	1,395,635	1,398,778
Total Liabilities	5,516,332	16,232,314
Commitments and Contingencies (Note 9)
Stockholders' Equity (Deficit):
Preferred Stock, $0.01 Par Value: 9,994,184 shares authorized; 3,750 designated Series A, 0 shares issued and outstanding at June 30, 2018 and December 31, 2017; 10,000 designated Series B, 0 and 600 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively; 10,000 shares designated Series C, 4,092 and 0 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively	41	6
Common Stock, $0.01 Par Value: 120,000,000 shares authorized; 42,382,880 and 17,257,255 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively	423,829	172,573
Additional Paid-In Capital	100,492,233	89,589,681
Accumulated Deficit	(87,498,357)	(91,816,655)
Accumulated Other Comprehensive Income	130,713	127,473
Total Stockholders' Equity (Deficit)	13,548,459	(1,926,922)
Total Liabilities and Stockholders' Equity (Deficit)	$ 19,064,791	$ 14,305,392

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	42,382,880	17,257,255
Common Stock, Shares, Outstanding	42,382,880	17,257,255
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	9,994,184	9,995,828
Series A Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Preferred Stock Designated Shares	3,750	3,750
Series B Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Issued	0	600
Preferred Stock, Shares Outstanding	0	600
Preferred Stock Designated Shares	10,000	10,000
Series C Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Issued	4,092	0
Preferred Stock, Shares Outstanding	4,092	0
Preferred Stock Designated Shares	10,000	10,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Collaboration Revenue	$ 242,012	$ 148,290	$ 1,338,020	$ 332,822
Operating Expenses:
Research and Development	(1,837,799)	(2,262,193)	(4,358,808)	(4,077,193)
General and Administrative	(1,202,531)	(1,212,891)	(2,156,579)	(2,502,035)
Total Operating Expenses	(3,040,330)	(3,475,084)	(6,515,387)	(6,579,228)
Operating Loss Before Other Expense	(2,798,318)	(3,326,794)	(5,177,367)	(6,246,406)
Other Income (Expense), Net:
Interest Income	18,367	236	18,393	497
Interest Expense	(304)	(305)	(608)	(608)
Total Other Income (Expense), Net	18,063	(69)	17,785	(111)
Net Loss	$ (2,780,255)	$ (3,326,863)	$ (5,159,582)	$ (6,246,517)
Net Loss per Common Share- Basic and Diluted	$ (0.07)	$ (0.28)	$ (0.19)	$ (0.55)
Weighted Average Shares Outstanding- Basic and Diluted	37,484,329	12,067,187	27,426,668	11,266,233
Other Comprehensive Loss:
Foreign Currency Translation Adjustments	$ 2,006	$ 2,856	$ 3,240	$ 2,921
Comprehensive Loss	$ (2,778,249)	$ (3,324,007)	$ (5,156,342)	$ (6,243,596)

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - 6 months ended Jun. 30, 2018 - USD ($)	Total	Previously Reported [Member]	Restatement Adjustment [Member]	Common Stock [Member]	Common Stock [Member]Previously Reported [Member]	Additional Paid In Capital [Member]	Additional Paid In Capital [Member]Previously Reported [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Other Comprehensive Income [Member]Previously Reported [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member]Previously Reported [Member]	Accumulated Deficit [Member]Restatement Adjustment [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock [Member]Previously Reported [Member]	Series B Preferred Stock [Member]Common Stock [Member]	Series B Preferred Stock [Member]Additional Paid In Capital [Member]	Series B Preferred Stock [Member]Preferred Stock [Member]	Series C Preferred Stock [Member]	Series C Preferred Stock [Member]Previously Reported [Member]	Series C Preferred Stock [Member]Common Stock [Member]	Series C Preferred Stock [Member]Additional Paid In Capital [Member]	Series C Preferred Stock [Member]Preferred Stock [Member]
Balance at Dec. 31, 2017	$ 7,550,958	$ (1,926,922)		$ 172,573	$ 172,573	$ 89,589,681	$ 89,589,681	$ 127,473	$ 127,473	$ (82,338,775)	$ (91,816,655)		$ 6	$ 6
Balance (in shares) at Dec. 31, 2017				17,257,255	17,257,255								600	600				0	0
Cumulative effect of change in accounting principle (note 2)			$ 9,477,880									$ 9,477,880
Stock-Based Compensation	290,856					290,856
Issuance of Stock in Offering, Net of Offering Costs of $1,141,238	10,108,762			$ 147,300		9,961,397												$ 65
Issuance of Stock in Offering, Net of Offering Costs of $1,141,238 (Shares)				14,730,000														6,536
Conversion of Preferred Stock into Common Stock													0		$ 4,000	$ (3,994)	$ (6)	$ 0		$ 76,388	$ (76,364)	$ (24)
Conversion of Preferred Stock into Common Stock (in shares)															400,000		(600)			7,638,750		(2,444)
Issuance of Common Shares from Warrant Exercises	754,225			$ 23,569		730,656
Issuance of Common Shares from Warrant Exercises (in shares)				2,356,875
Foreign Currency Translation Adjustment	3,240							3,240
Net Loss	(5,159,582)									(5,159,582)
Balance at Jun. 30, 2018	$ 13,548,459			$ 423,829		$ 100,492,233		$ 130,713		$ (87,498,357)			$ 0					$ 41
Balance (in shares) at Jun. 30, 2018				42,382,880									0					4,092

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Operating Activities
Net Loss	$ (5,159,582)	$ (6,246,517)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Depreciation and Amortization	15,932	9,072
Stock-Based Compensation	290,856	512,141
Changes in Operating Assets and Liabilities:
Prepaid Expenses and Other Current Assets	14,746	(353,618)
Refundable Tax Credit Receivable	10,076	198
Grant Receivable	0	(108,729)
Other Assets	0	(418)
Accounts Payable	(350,064)	(441,216)
Deferred Revenue	577,208	4,636,400
Unbilled Revenue	(689,928)	0
Accrued Expenses	(768,996)	(504,478)
Net Cash Used in Operating Activities	(6,059,752)	(2,497,165)
Financing Activities
Proceeds from Stock Offerings, Net of Offering Costs	10,108,762	10,589,183
Exercise of Common Stock Options	0	40,718
Exercise of Warrants	754,225
Equipment Financing Payments	(6,322)	(6,323)
Net Cash Provided by Financing Activities	10,856,665	10,623,578
Effect of Exchange Rate Changes on Cash	1,861	1,500
Net Increase in Cash	4,798,774	8,127,913
Cash, Including Restricted Cash, Beginning of Period	7,851,029	3,680,224
Cash, Including Restricted Cash, End of Period	12,649,803	11,808,137
Supplemental Disclosure of Noncash Investing and Financing Activities
Conversion of Preferred Stock into Common Stock	$ 36,637	$ 9,300

Organization, Business

Organization, Business	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	1. Organization, Business EyeGate Pharmaceuticals, Inc. (“EyeGate” or the “Company”), a Delaware corporation, began operations in December 2004 and is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate’s first product in clinical trials incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, EGP-437, that is delivered into the ocular tissues though its proprietary iontophoresis drug delivery system, the EyeGate® II Delivery System. The Company is developing the EyeGate® II Delivery System and EGP-437 combination product (together, the “EGP-437 Product”) for the treatment of various inflammatory conditions of the eye, including anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, post-cataract surgery inflammation and pain, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the retina. For EyeGate’s second product, the Company’s wholly owned subsidiary, Jade Therapeutics, Inc. (“Jade”), develops locally-administered, polymer-based products designed to treat poorly-served ophthalmic indications. EyeGate and Jade are an integrated line of business developing ophthalmic solutions for a variety of ocular diseases and disorders. As of June 30, 2018, there were 42,382,880 shares of Common Stock outstanding, no shares of Series A Preferred Stock outstanding, no shares of Series B Preferred Stock outstanding, and 4,092 shares of Series C Preferred Stock outstanding. Since its inception, EyeGate has devoted substantially all of its efforts to business planning, research and development, and raising capital. The accompanying Condensed Consolidated Financial Statements have been prepared assuming that EyeGate will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. At June 30, 2018, EyeGate had Cash and Cash Equivalents of $12,604,803, and an Accumulated Deficit of $87,498,357. EyeGate has incurred losses and negative cash flows since inception, and future losses are anticipated. The Company anticipates having sufficient cash to fund planned operations for approximately twelve months from June 30, 2018, however, the acceleration or reduction of cash outflows by Company management can significantly impact the timing for raising additional capital to complete development of its products. To continue development, EyeGate will need to raise additional capital through equity financing, license agreements, and/or additional U.S. government grants. Although the Company successfully completed its IPO, a follow-on public offering, a registered direct offering, two public offerings, and sales under an at-the-market equity offering, additional capital may not be available on terms favorable to EyeGate, if at all. On May 6, 2016, the SEC declared effective EyeGate’s registration statement on Form S-3, registering a total of $100,000,000 of its securities for sale to the public from time to time in what is known as a “shelf offering”. The Company does not know if any future offerings, including offerings pursuant to its shelf registration statement, will succeed. Accordingly, no assurances can be given that Company management will succeed in these endeavors. The Company’s recurring losses from operations have caused management to determine there is substantial doubt about the Company’s ability to continue as a going concern. The Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries, EyeGate Pharma S.A.S. and Jade (since date of acquisition), collectively referred to as “the Company”. All inter-company balances and transactions have been eliminated in consolidation. These Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Certain information and disclosures normally included in Condensed Consolidated Financial Statements prepared in accordance with U.S. GAAP have been condensed or eliminated. Accordingly, these unaudited Condensed Consolidated Financial Statements should be read in conjunction with the annual financial statements of the Company as of and for the year ended December 31, 2017. Unaudited Interim Financial Information The accompanying interim financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which consist of normal recurring adjustments, necessary for a fair presentation of the results of operations for the periods presented. The year-end balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for an interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The Company makes significant estimates and assumptions in recording the accruals for its clinical trial and research activities, establishing the useful lives of intangible assets and property and equipment, and conducting impairment reviews of long-lived assets. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Although the Company monitors and regularly assesses these estimates, actual results could differ significantly from these estimates. The Company records changes in estimates in the period that it becomes aware of the change. Research and Development Expenses The Company expenses research and development (“R&D”) expenditures as incurred. R&D expenses are comprised of costs incurred in performing R&D activities, including salaries, benefits, facilities, research-related overhead, sponsored research costs, contracted services, license fees, expenses related to generating, filing, and maintaining intellectual property, and other external costs. Because the Company believes that, under its current process for developing its products, the viability of the products is essentially concurrent with the establishment of technological feasibility, no costs have been capitalized to date. In-process Research and Development The Company records in-process R&D projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use. For in-process R&D projects acquired in business combinations, the Company capitalizes the in-process R&D project and periodically evaluates this asset for impairment until the R&D process has been completed. Once the R&D process is complete, the Company amortizes the R&D asset over its remaining useful life. At June 30, 2018, the Company has recorded $3,912,314 of in-process R&D, as part of goodwill and in-process R&D on the Condensed Consolidated Balance Sheet. Accrued Clinical Expenses As part of the Company’s process of preparing the Condensed Consolidated Financial Statements, the Company is required to estimate its accrued expenses. This process includes reviewing open contracts and purchase orders, communicating with its applicable personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. The majority of the Company’s service providers invoice monthly in arrears for services performed. The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at the time. The Company periodically confirms the accuracy of these estimates with the service providers and makes adjustments if necessary. Related Party Transactions The Company has entered into certain related-party transactions, making payments for services to one vendor, seven consultants and a public university for the three months ending June 30, 2018, all of whom also are stockholders of the Company. These transactions generally are ones that involve a stockholder or option holder of the Company to whom we also make payments during the year, typically as a consultant or a service provider. The amounts recorded or paid are not material to the accompanying Condensed Consolidated Financial Statements. Net Loss per Share The computation of Net Loss per Common Share – Basic and Diluted, is based on the weighted-average number of shares outstanding of Common Stock. In computing diluted loss per share, no effect has been given to the shares of common stock issuable upon the conversion or exercise of the following dilutive securities, as the Company’s net loss would make the effect anti-dilutive. June 30, 2018 (unaudited) June 30, 2017 (unaudited) Common Stock Warrants 42,255,336 9,519,403 Employee Stock Options 2,106,035 1,842,255 Preferred Stock 12,787,500 400,000 Total Shares of Common Stock Issuable 57,148,871 11,761,658 Fair Value of Financial Instruments The carrying amounts of Accounts Receivable and Accounts Payable approximate their fair values due to the short-term nature of these items. As of June 30, 2018 and December 31, 2017, the fair value of the Company’s money market funds and contingent consideration was $0 and $1,210,000, and $750,965 and $1,210,000, respectively. At June 30, 2018 and December 31, 2017, the Company had no other assets or liabilities that are subject to fair value methodology and estimation in accordance with U.S. GAAP. Revenue Recognition The Company’s revenues are generated primarily through arrangements which generally contain multiple elements, or deliverables, including licenses and R&D activities to be performed by the Company on behalf of the licensor or grantor. Payments to EyeGate under these arrangements typically include one or more of the following: (1) nonrefundable, upfront license fees, (2) funding of discovery research efforts on a full-time equivalent basis, (3) reimbursement of research, development and intellectual property costs, (4) milestone payments, and (5) royalties on future product sales. On July 9, 2015, the Company entered into an exclusive, worldwide licensing agreement with a subsidiary of Valeant Pharmaceuticals International, Inc. (“Valeant”), through which the Company granted to Valeant an exclusive, worldwide commercial and manufacturing right to the Company’s EGP-437 Product in the field of anterior uveitis, as well as a right of last negotiation to license its EGP-437 Product for indications other than anterior uveitis (the “Valeant Agreement”). There are four principal R&D milestones under the Valeant Agreement: (i) the Phase 3 Clinical Trial, (ii) the Endothelial Cell Count Safety Trial (a trial to determine that treatment has not adversely affected a patient’s corneal endothelial cell density), (iii) the CMC Validation, and (iv) the New Drug Application, or “NDA”, filing with the FDA (collectively, the “Four Milestones”, and each individually, a “Milestone”). Under the Valeant Agreement, Valeant paid to the Company an initial upfront payment of $1.0 million and the Company is eligible to receive milestone payments totaling up to $32.5 million, upon and subject to the achievement of certain specified development and commercial progress of the EGP-437 Product for the treatment of anterior uveitis. The Company has received milestone payments totaling $5.1 million through June 30, 2018. The Company receives payments both when it crosses certain thresholds on the way to each Milestone (each, a “Progress Payment”), as well as once it achieves each Milestone. The Company is entitled to retain all of these payments. In accordance with its former revenue recognition policy, through December 31, 2017 the initial upfront payment and milestone payments were recorded as Deferred Revenue. In addition, the Company is eligible under the Valeant Agreement to receive royalties based on a specified percent of net sales of its EGP-437 Product for the field of anterior uveitis throughout the world, subject to adjustment in certain circumstances. On February 21, 2017, the Company entered into another exclusive, worldwide licensing agreement with a subsidiary of Valeant (the “New Valeant Agreement”), through which the Company granted Valeant exclusive, worldwide commercial and manufacturing rights to its EGP-437 Product in the field of ocular iontophoretic treatment for post-operative ocular inflammation and pain in ocular surgery patients (the “New Field”). Under the New Valeant Agreement, Valeant paid the Company an initial upfront payment of $4.0 million, and the Company is eligible to receive milestone payments totaling up to approximately $99.0 million, upon and subject to the achievement of certain specified developmental and commercial progress of the EGP-437 Product for the New Field. The Company has received milestone payments totaling $3.4 million through June 30, 2018. In accordance with its former revenue recognition policy, through December 31, 2017 the initial upfront payment and milestone payments were recorded as Deferred Revenue. In addition, the Company is eligible under the New Valeant Agreement to receive royalties based on a specified percent of net sales of its EGP-437 Product for the New Field throughout the world, subject to adjustment in certain circumstances. In May 2014, the FASB issued ASU No. 2014-09, Revenues from Contracts with Customers The Company did not elect to early adopt and adopted the new standard on January 1, 2018, using the modified retrospective method, which resulted in a cumulative effect adjustment in the amount of $9.5 million to beginning 2018 accumulated deficit and to deferred and unbilled revenue for the Valeant contracts impacted by the adoption of the new standard. The changes to the method and/or timing of the Company’s revenue recognition associated with the adoption of the new standard primarily relate to the determination that there is one performance obligation in each contract with Valeant and that the license combined with the R&D services is the performance obligation. The cumulative effect of initially applying the new revenue recognition guidance to the Company’s Condensed Consolidated Balance Sheet on January 1, 2018 was as follows: Balance as of ‎ December 31, ‎ 2017 Cumulative Impact ‎ from Adopting New ‎ Revenue Guidance Balance as of ‎ January 1, 2018 Assets: Unbilled Revenue $ - $ 116,280 $ 116,280 Liabilities: Deferred Revenue 12,313,600 (9,361,600 ) 2,952,000 Stockholders' Equity: Accumulated Deficit $ (91,816,655 ) $ 9,477,880 $ (82,338,775 ) The impact from adopting the new revenue recognition guidance on the Company’s Condensed Consolidated Balance Sheet for the six months ending June 30, 2018 was as follows: As ‎ Reported Previous ‎ Accounting ‎ Guidance Impact from ‎ Adopting New ‎ Revenue ‎ Guidance Liabilities: Deferred Revenue $ 2,723,000 $ 13,341,100 $ (10,618,100 ) Stockholders' Equity: Accumulated Deficit $ (87,498,357 ) $ (98,116,457 ) $ 10,618,100 The impact from adopting the new revenue recognition guidance on the Company’s Condensed Consolidated Statement of Operations and Comprehensive Loss for the three and six months ended June 30, 2018 was as follows: Three Months Ended Six Months Ended As ‎ Reported Previous ‎ Accounting ‎ Guidance Impact from ‎ Adopting ‎ New Revenue ‎ Guidance As ‎ Reported Previous ‎ Accounting ‎ Guidance Impact from ‎ Adopting New ‎ Revenue ‎ Guidance Collaboration Revenue $ 242,012 $ - $ 242,012 $ 1,338,020 $ - $ 1,338,020 Operating Loss Before Other Expenses (2,798,318 ) (3,040,330 ) 242,012 (5,177,367 ) (6,515,387 ) 1,338,020 Net Loss (2,780,255 ) (3,022,267 ) 242,012 (5,159,582 ) (6,497,602 ) 1,338,020 Comprehensive Loss $ (2,778,249 ) $ (3,020,261 ) $ 242,012 $ (5,156,342 ) $ (6,494,362 ) $ 1,338,020 Under this new guidance, the Company recognizes revenue when its customer obtains control of promised services, in an amount that reflects the consideration which the Company expects to receive in exchange for those services. To determine whether arrangements are within the scope of this new guidance, the Company performs the following five steps: (i) identifies the contract with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when (or as) the Company satisfies its performance obligation. The Company applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Upon adoption of ASU No. 2014-09, the Company recognizes revenue from the transaction price applied to each single performance obligation over time as milestones are reached for each performance obligation. The Company only recognizes revenue on those milestones that are within the Company’s control and any constrained variable consideration that requires regulatory approval will only be included in the transaction price when performance is complete. The below table represents the changes in the Company’s contract assets and contract liabilities: June 30, 2018 January 1, 2018 Contract Asset: Unbilled Revenue $ - $ 116,280 Contract Liabilities: Deferred Revenue $ 2,723,000 $ 2,952,000 Three Months ‎ Ended Six Months ‎ Ended June 30, 2018 June 30, 2018 Revenue recognized in the period from: Amounts included in contract liability at the beginning of the period $ 137,000 $ 229,000 In addition, the Company may receive government grant funds for specified ocular therapeutic research activities. Revenue under these grants will be recorded when the Company performs the activities specified by the terms of each grant and is entitled to the funds. Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases see On January 26, 2017, the FASB issued ASU No. 2017-04, Intangibles Goodwill and Other In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	3. Property and Equipment Property and equipment at June 30, 2018 (unaudited) and December 31, 2017 consists of the following: Estimated Useful Life (Years) June 30, 2018 December 31, 2017 Laboratory Equipment 3 $ 42,576 $ 42,576 Office Furniture 5 14,430 14,430 Leasehold Improvements 2 22,569 22,569 Total Property and Equipment, Gross 79,575 79,575 Less: Accumulated Depreciation 39,756 23,824 Total Property and Equipment, Net $ 39,819 $ 55,751 Depreciation expense was $7,966 and $4,536 for the three-month periods ended June 30, 2018 and 2017, respectively, and $15,932 and $9,072 for the six-month periods ended June 30, 2018 and 2017, respectively.

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2018
Accrued Liabilities [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. Accrued Expenses Accrued expenses consist of the following: June 30, 2018 (unaudited) December 31, 2017 Payroll and Benefits $ 564,977 $ 788,551 Clinical Trials 304,530 807,322 Professional Fees 153,334 149,273 Consulting 10,796 57,487 Short-Term Portion of Capital Lease Obligation 8,035 11,214 Total Accrued Expenses $ 1,041,672 $ 1,813,847

Debt

Debt	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	5. Debt The Company has no indebtedness other than trade and accounts payable and capital lease obligations in the ordinary course of business as of June 30, 2018 and December 31, 2017.

Capital Stock

Capital Stock	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	6. Capital Stock On May 24, 2016, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent”), to create an at the market equity program under which the Company can from time to time offer and sell up to 1,319,289 shares of its Common Stock through the Sales Agent. On February 21, 2017, the Company authorized the Sales Agent to restart sales under the ATM Agreement for maximum aggregate gross proceeds of up to $3,285,798. During the first quarter of 2017, the Company sold 642,150 shares of Common Stock under this agreement for total net proceeds to the Company from this offering, after deducting the placement agent fees and offering expenses, of approximately $1.8 million. No further shares of Common Stock have been sold pursuant to the ATM Agreement. On June 14, 2017, the Company closed on the sale of its equity securities in connection with a public offering, described below, and as a result, the Company is restricted from issuing any shares pursuant to the ATM Agreement for a period of twenty-four months following the closing date of the offering. However, this restriction is suspended for any sale of shares of Common Stock under the ATM Agreement that is above $3.00 per share. On June 14, 2017, the Company completed a public offering of 5,336,667 shares of Common Stock and 1,995 shares of Series B Preferred Stock (convertible into 1,330,000 shares of Common Stock), along with warrants to purchase 6,666,667 shares of Common Stock. The total net proceeds to the Company from the offering, after deducting the placement agent fees and offering expenses, were approximately $8.8 million. Additionally, the investors received, for each share of Common Stock, or for each share of Common Stock issuable upon conversion of a share of Series B Preferred Stock purchased in the public offering, warrants to purchase one share of Common Stock at an exercise price of $1.50 per share, which totaled warrants to purchase an aggregate of 6,666,667 shares of Common Stock. The warrants issued to investors became initially exercisable immediately upon issuance and terminate on June 14, 2022, five years following the date of issuance. Concurrently with the closing of the public offering, a holder elected to convert 675 shares of Series B Preferred Stock into 450,000 shares of Common Stock. Subsequently, on June 15, 2017 and April 9, 2018, holders converted 1,320 shares of Series B Preferred stock into 880,000 shares of Common Stock. On April 17, 2018, the Company completed a public offering of 14,730,000 shares of Common Stock and 6,536.4 shares of Series C Preferred Stock (convertible into 20,426,250 shares of Common Stock), along with warrants to purchase 35,156,250 shares of Common Stock. The total net proceeds to the Company from the offering, after deducting the placement agent fees and offering expenses, were approximately $10.1 million. Additionally, the investors received, for each share of Common Stock, or for each share of Common Stock issuable upon conversion of a share of Series C Preferred Stock purchased in the public offering, warrants to purchase one share of Common Stock at an exercise price of $0.32 per share, which totaled warrants to purchase an aggregate of 35,156,250 shares of Common Stock. The warrants issued to investors became initially exercisable immediately upon issuance and terminate on April 17, 2023, five years following the date of issuance. Concurrently with the closing of the public offering, a holder elected to convert 1,400 shares of Series C Preferred Stock into 4,375,000 shares of Common Stock. Subsequently, on April 18, 2018, April 23, 2018, and April 30, 2018, holders converted 1,044.4 shares of Series C Preferred stock into 3,263,750 shares of Common Stock. At June 30, 2018, the Company had 100,000,000 authorized shares of Common Stock, $0.01 par value, of which 42,382,880 shares were outstanding. At June 30, 2018, the Company had 9,994,184 authorized shares of Preferred Stock, $0.01 par value, of which 3,750 shares were designated as Series A Preferred Stock and 0 shares are issued and outstanding, 10,000 shares were designated as Series B Preferred Stock and 0 shares are issued and outstanding, and 10,000 shares were designated as Series C Preferred Stock and 4,092 shares are issued and outstanding. At June 30, 2018, there were 0 shares of Common Stock underlying the outstanding shares of Series A Preferred Stock, 0 shares of Common Stock underlying the outstanding shares of Series B Preferred Stock, and 12,787,500 shares of Common Stock underlying the outstanding shares of Series C Preferred Stock.

Warrants

Warrants	6 Months Ended
	Jun. 30, 2018
Warrants [Abstract]
Warrants Disclosure [Text Block]	7. Warrants At June 30, 2018, the following warrants were outstanding: Number of Awards Weighted Average Exercise Price Weighted Average Remaining Term in Years Outstanding at December 31, 2017 9,455,961 $ 3.26 4.23 Issued 35,156,250 0.32 4.80 Exercised (2,356,875 ) 0.32 4.80 Outstanding at June 30, 2018 42,255,336 $ 0.98 4.56 All of the warrant agreements provide for a cashless exercise in the event a registration statement covering the issuance of the shares of common stock underlying the warrants is not effective, whereby the number of warrants to be issued will be reduced by the number of shares which could be purchased from the proceeds of the exercise of the respective warrant. The outstanding warrants expire from 2020 through 2025.

Equity Incentive Plan

Equity Incentive Plan	6 Months Ended
	Jun. 30, 2018
Share Based Compensation Option And Incentive Plan [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	8. Equity Incentive Plan In 2005, the Company approved the 2005 Equity Incentive Plan (the “2005 Plan”). The 2005 Plan provides for the granting of options, restricted stock or other stock-based awards to employees, officers, directors, consultants and advisors. During 2010, the maximum number of shares of Common Stock that may be issued pursuant to the 2005 Plan was increased to 891,222 shares. The Board of Directors (the “Board”) is responsible for administration of the 2005 Plan. The Company’s Board determines the term of each option, the option exercise price, the number of shares for which each option is granted and the rate at which each option is exercisable. Incentive stock options may be granted to any officer or employee at an exercise price per share of not less than the fair value per common share on the date of the grant (not less than 110% of fair value in the case of holders of more than 10% of the Company’s voting stock) and with a term not to exceed ten years from the date of the grant (five years for incentive stock options granted to holders of more than 10% of the Company’s voting stock). Nonqualified stock options may be granted to any officer, employee, consultant or director at an exercise price per share of not less than the par value per share. Following adoption of the 2014 Equity Incentive Plan (the “2014 Plan”), no further grants were made under the 2005 Plan. The Company’s Board adopted the 2014 Plan and the Employee Stock Purchase Plan (the “ESPP”) and the Company’s Stockholders approved the 2014 Plan and the ESPP Plan in February 2015. As of June 30, 2018, the maximum number of shares of Common Stock that may be issued pursuant to the 2014 Plan and the ESPP was 2,040,123 and 170,567 shares, respectively. In January 2018, the number of shares of common stock issuable under the 2014 Plan automatically increased by 350,000 shares pursuant to the terms of the 2014 Plan. These additional shares are included in the total of 2,040,123 shares issuable under the 2014 Plan. The following is a summary of stock option activity for the six months ended June 30, 2018: Number of Options Weighted- Average Exercise Price Weighted-Average Contractual Life (In Years) Outstanding at December 31, 2017 1,893,003 $ 2.49 5.40 Granted 275,500 0.57 9.65 Forfeited (1,500 ) 0.83 Expired (60,968 ) 0.80 Outstanding at June 30, 2018 2,106,035 $ 2.29 4.66 Exercisable at June 30, 2018 1,429,484 $ 2.65 3.95 Vested and Expected to Vest at June 30, 2018 1,429,484 $ 2.65 3.95 On February 28, 2018, the Board approved the grant of options to purchase 275,000 shares of its common stock to sixteen employees. On March 21, 2018, the Board approved the grant of options to purchase 500 shares of its common stock to one employee. All grants were pursuant to the 2014 Plan. In general, options granted under the 2014 Plan vest with respect to one-third of the underlying shares on the one-year anniversary of the grant date and the remainder ratably over a 24-month period. For the six months ended June 30, 2018 and 2017, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions: 2018 2017 Risk-Free Interest Rate 1.82% 1.82% Expected Life 7.00 years 7.29 years Expected Volatility 159% 172% Expected Dividend Yield 0% 0% Using the Black-Scholes Option Pricing Model, the estimated weighted average fair value of an option to purchase one share of common stock granted during the six months ended June 30, 2018 and 2017 was $0.57 and $1.47, respectively. The total stock-based compensation expense for employees and non-employees is included in the accompanying Condensed Consolidated Statements of Operations and as follows: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Research and Development $ 49,897 $ 62,242 $ 106,975 $ 107,994 General and Administrative 95,412 172,998 183,881 404,147 $ 145,309 $ 235,240 $ 290,856 $ 512,141 The fair value of options granted for the six months ended June 30, 2018 and June 30, 2017 was approximately $151,000 and $530,000, respectively. The fair value of restricted stock granted for the six months ended June 30, 2017 was approximately $158,000. As of June 30, 2018 and June 30, 2017, there was approximately $805,000 and $1,295,000 of total unrecognized compensation expense related to unvested stock-based compensation arrangements granted, which cost is expected to be recognized over a weighted-average period of 1.57 and 2.12 years, respectively. The aggregate intrinsic value of stock options outstanding and exercisable at June 30, 2018 and June 30, 2017 was approximately $0 and $326,000, respectively. The intrinsic value of stock options exercised during the six months ended June 30, 2018 and June 30, 2017 was approximately $0 and $78,000, respectively. At June 30, 2018, there were 192,411 options available under the 2014 Plan and 117,090 shares available under the Company’s ESPP.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	9. Commitments and Contingencies Leases The Company is a party to a real property operating lease for the rental of office space in Waltham, Massachusetts of up to 4,516 square feet, that is used for its corporate headquarters. This lease terminates in December 2019. On July 6, 2016, the Company entered into a real property operating lease for office and laboratory space of approximately 2,300 square feet in Salt Lake City, Utah. This lease terminates in June 2019. Estimated future minimum lease payments for the years ended December 31, 2018 and 2019 are approximately $86,000 and $144,000, respectively. The Company is a party to two nominal equipment capital lease agreements, one for a three-year term and one for a two-year term, for the use of scientific instruments in its Salt Lake City laboratory. License Agreements The Company is a party to six license agreements as described below. Four of the six license agreements require the Company to pay royalties or fees to the licensor based on Revenue related to the licensed technology, and the agreements with Valeant require Valeant to pay royalties to the Company based on revenue related to the licensed technology. On February 15, 1999, the Company entered in to an exclusive worldwide license agreement with the University of Miami School of Medicine to license technology relating to the Company’s EyeGate® II Delivery System. This agreement, which was amended in December 2005, requires the Company to pay to the University of Miami an annual license fee of $12,500. This license also requires payments to the University of Miami upon the Company’s achievement of certain milestones. Unless terminated pursuant to the license agreement, this license will expire 12 years after the date of the first commercial sale of a product containing the licensed technology. On July 23, 1999, the Company entered into a perpetual Transaction Protocol agreement with Francine Behar-Cohen to acknowledge the Company’s right to use certain patents that Ms. Behar-Cohen had certain ownership rights with respect to and which are used in the Company’s EGP-437 Combination Product. The agreement also provides for the Company to pay Ms. Behar-Cohen a fee based on a percentage of the pre-tax turnover generated from sales of the Company’s EGP-437 Combination Product relating to its inclusion of the EyeGate® II Delivery System. The fees due under the agreement expired in January 2018, but the Company continues to maintain its rights under the agreement. On September 12, 2013, Jade entered into an agreement with BioTime, Inc. granting to it the exclusive worldwide right to commercialize cross-linked thiolated carboxymethyl hyaluronic acid (“CMHA-S”) for ophthalmic treatments in humans. The agreement calls for a license issue fee paid to BioTime of $50,000, and requires the Company (through its Jade subsidiary) to pay an annual fee of $30,000 and royalties to BioTime based on revenue relating to any product incorporating the CMHA-S technology. The agreement expires when patent protection for the CMHA-S technology lapses. On July 9, 2015, the Company entered into an exclusive worldwide licensing agreement with a subsidiary of Valeant through which EyeGate has granted Valeant exclusive, worldwide commercial and manufacturing rights to its EGP-437 Product in the field of anterior uveitis, as well as a right of last negotiation to license the EGP-437 Product for other indications. Under the agreement, Valeant paid the Company an upfront payment of $1.0 million. The Company is eligible to receive milestone payments totaling up to $32.5 million, upon and subject to the achievement of certain specified developmental and commercial milestones. In addition, the Company is eligible to receive royalties based on a specified percent of net sales of the Product throughout the world, subject to adjustment in certain circumstances. On June 17, 2016, the Company entered into an exclusive worldwide license agreement with the University of Utah Research Foundation to further the commercial development of the NASH technology, together with alkylated HA. The agreement calls for payments due to the University of Utah, consisting of a license grant fee of $15,000 due within 30 days of signing, and an annual licensing fee, initially $5,000, and escalating ratably up to $20,000 in 2021. On February 21, 2017, the Company entered into an exclusive, worldwide licensing agreement with a subsidiary of Valeant (the “New Valeant Agreement”), through which the Company granted Valeant exclusive, worldwide commercial and manufacturing rights to its EGP-437 Product in the field of ocular iontophoretic treatment for post-operative ocular inflammation and pain in ocular surgery patients (the “New Field”). Under the New Valeant Agreement, Valeant paid the Company an initial upfront payment of $4.0 million, and the Company is eligible to receive milestone payments totaling up to approximately $99.0 million, upon and subject to the achievement of certain specified developmental and commercial progress of the EGP-437 Product for the New Field. In addition, the Company is eligible under the New Valeant Agreement to receive royalties based on a specified percent of net sales of its EGP-437 Product for the New Field throughout the world, subject to adjustment in certain circumstances.

Employee Benefit Plans

Employee Benefit Plans	6 Months Ended
	Jun. 30, 2018
Postemployment Benefits [Abstract]
Compensation and Employee Benefit Plans [Text Block]	10. Employee Benefit Plans The Company has an employee benefit plan for its United States-based employees under Section 401(k) of the Internal Revenue Code. The Plan allows all eligible employees to make contributions up to a specified percentage of their compensation. Under the Plan, the Company may, but is not obligated to, match a portion of the employee contribution up to a defined maximum. The Company made no matching contribution for the six months ended June 30, 2018 and 2017.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Events [Text Block]	11. Subsequent Events On July 10, 2018, following the 2018 Annual Meeting of Stockholders of the Company (the “Annual Meeting”), the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation that increased the number of authorized shares of Common Stock from 100,000,000 to 120,000,000. The stockholders of the Company also approved an amendment to the Company’s 2014 Equity Incentive Plan at the Annual Meeting to increase the maximum number of shares authorized for issuance thereunder by 6,000,000, which amendment became effective following the Annual Meeting.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation [Policy Text Block]	Basis of Presentation and Principles of Consolidation The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries, EyeGate Pharma S.A.S. and Jade (since date of acquisition), collectively referred to as “the Company”. All inter-company balances and transactions have been eliminated in consolidation. These Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Certain information and disclosures normally included in Condensed Consolidated Financial Statements prepared in accordance with U.S. GAAP have been condensed or eliminated. Accordingly, these unaudited Condensed Consolidated Financial Statements should be read in conjunction with the annual financial statements of the Company as of and for the year ended December 31, 2017.
Unaudited Interim Financial Information [Policy Text Block]	Unaudited Interim Financial Information The accompanying interim financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which consist of normal recurring adjustments, necessary for a fair presentation of the results of operations for the periods presented. The year-end balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for an interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The Company makes significant estimates and assumptions in recording the accruals for its clinical trial and research activities, establishing the useful lives of intangible assets and property and equipment, and conducting impairment reviews of long-lived assets. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Although the Company monitors and regularly assesses these estimates, actual results could differ significantly from these estimates. The Company records changes in estimates in the period that it becomes aware of the change.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses The Company expenses research and development (“R&D”) expenditures as incurred. R&D expenses are comprised of costs incurred in performing R&D activities, including salaries, benefits, facilities, research-related overhead, sponsored research costs, contracted services, license fees, expenses related to generating, filing, and maintaining intellectual property, and other external costs. Because the Company believes that, under its current process for developing its products, the viability of the products is essentially concurrent with the establishment of technological feasibility, no costs have been capitalized to date.
In Process Research and Development, Policy [Policy Text Block]	In-process Research and Development The Company records in-process R&D projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use. For in-process R&D projects acquired in business combinations, the Company capitalizes the in-process R&D project and periodically evaluates this asset for impairment until the R&D process has been completed. Once the R&D process is complete, the Company amortizes the R&D asset over its remaining useful life. At June 30, 2018, the Company has recorded $3,912,314 of in-process R&D, as part of goodwill and in-process R&D on the Condensed Consolidated Balance Sheet.
Accrued Clinical Expenses [Policy Text Block]	Accrued Clinical Expenses As part of the Company’s process of preparing the Condensed Consolidated Financial Statements, the Company is required to estimate its accrued expenses. This process includes reviewing open contracts and purchase orders, communicating with its applicable personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. The majority of the Company’s service providers invoice monthly in arrears for services performed. The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at the time. The Company periodically confirms the accuracy of these estimates with the service providers and makes adjustments if necessary.
Related Party Transactions [Policy Text Block]	Related Party Transactions The Company has entered into certain related-party transactions, making payments for services to one vendor, seven consultants and a public university for the three months ending June 30, 2018, all of whom also are stockholders of the Company. These transactions generally are ones that involve a stockholder or option holder of the Company to whom we also make payments during the year, typically as a consultant or a service provider. The amounts recorded or paid are not material to the accompanying Condensed Consolidated Financial Statements.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The computation of Net Loss per Common Share – Basic and Diluted, is based on the weighted-average number of shares outstanding of Common Stock. In computing diluted loss per share, no effect has been given to the shares of common stock issuable upon the conversion or exercise of the following dilutive securities, as the Company’s net loss would make the effect anti-dilutive. June 30, 2018 (unaudited) June 30, 2017 (unaudited) Common Stock Warrants 42,255,336 9,519,403 Employee Stock Options 2,106,035 1,842,255 Preferred Stock 12,787,500 400,000 Total Shares of Common Stock Issuable 57,148,871 11,761,658
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying amounts of Accounts Receivable and Accounts Payable approximate their fair values due to the short-term nature of these items. As of June 30, 2018 and December 31, 2017, the fair value of the Company’s money market funds and contingent consideration was $0 and $1,210,000, and $750,965 and $1,210,000, respectively. At June 30, 2018 and December 31, 2017, the Company had no other assets or liabilities that are subject to fair value methodology and estimation in accordance with U.S. GAAP.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company’s revenues are generated primarily through arrangements which generally contain multiple elements, or deliverables, including licenses and R&D activities to be performed by the Company on behalf of the licensor or grantor. Payments to EyeGate under these arrangements typically include one or more of the following: (1) nonrefundable, upfront license fees, (2) funding of discovery research efforts on a full-time equivalent basis, (3) reimbursement of research, development and intellectual property costs, (4) milestone payments, and (5) royalties on future product sales. On July 9, 2015, the Company entered into an exclusive, worldwide licensing agreement with a subsidiary of Valeant Pharmaceuticals International, Inc. (“Valeant”), through which the Company granted to Valeant an exclusive, worldwide commercial and manufacturing right to the Company’s EGP-437 Product in the field of anterior uveitis, as well as a right of last negotiation to license its EGP-437 Product for indications other than anterior uveitis (the “Valeant Agreement”). There are four principal R&D milestones under the Valeant Agreement: (i) the Phase 3 Clinical Trial, (ii) the Endothelial Cell Count Safety Trial (a trial to determine that treatment has not adversely affected a patient’s corneal endothelial cell density), (iii) the CMC Validation, and (iv) the New Drug Application, or “NDA”, filing with the FDA (collectively, the “Four Milestones”, and each individually, a “Milestone”). Under the Valeant Agreement, Valeant paid to the Company an initial upfront payment of $1.0 million and the Company is eligible to receive milestone payments totaling up to $32.5 million, upon and subject to the achievement of certain specified development and commercial progress of the EGP-437 Product for the treatment of anterior uveitis. The Company has received milestone payments totaling $5.1 million through June 30, 2018. The Company receives payments both when it crosses certain thresholds on the way to each Milestone (each, a “Progress Payment”), as well as once it achieves each Milestone. The Company is entitled to retain all of these payments. In accordance with its former revenue recognition policy, through December 31, 2017 the initial upfront payment and milestone payments were recorded as Deferred Revenue. In addition, the Company is eligible under the Valeant Agreement to receive royalties based on a specified percent of net sales of its EGP-437 Product for the field of anterior uveitis throughout the world, subject to adjustment in certain circumstances. On February 21, 2017, the Company entered into another exclusive, worldwide licensing agreement with a subsidiary of Valeant (the “New Valeant Agreement”), through which the Company granted Valeant exclusive, worldwide commercial and manufacturing rights to its EGP-437 Product in the field of ocular iontophoretic treatment for post-operative ocular inflammation and pain in ocular surgery patients (the “New Field”). Under the New Valeant Agreement, Valeant paid the Company an initial upfront payment of $4.0 million, and the Company is eligible to receive milestone payments totaling up to approximately $99.0 million, upon and subject to the achievement of certain specified developmental and commercial progress of the EGP-437 Product for the New Field. The Company has received milestone payments totaling $3.4 million through June 30, 2018. In accordance with its former revenue recognition policy, through December 31, 2017 the initial upfront payment and milestone payments were recorded as Deferred Revenue. In addition, the Company is eligible under the New Valeant Agreement to receive royalties based on a specified percent of net sales of its EGP-437 Product for the New Field throughout the world, subject to adjustment in certain circumstances. In May 2014, the FASB issued ASU No. 2014-09, Revenues from Contracts with Customers The Company did not elect to early adopt and adopted the new standard on January 1, 2018, using the modified retrospective method, which resulted in a cumulative effect adjustment in the amount of $9.5 million to beginning 2018 accumulated deficit and to deferred and unbilled revenue for the Valeant contracts impacted by the adoption of the new standard. The changes to the method and/or timing of the Company’s revenue recognition associated with the adoption of the new standard primarily relate to the determination that there is one performance obligation in each contract with Valeant and that the license combined with the R&D services is the performance obligation. The cumulative effect of initially applying the new revenue recognition guidance to the Company’s Condensed Consolidated Balance Sheet on January 1, 2018 was as follows: Balance as of ‎ December 31, ‎ 2017 Cumulative Impact ‎ from Adopting New ‎ Revenue Guidance Balance as of ‎ January 1, 2018 Assets: Unbilled Revenue $ - $ 116,280 $ 116,280 Liabilities: Deferred Revenue 12,313,600 (9,361,600 ) 2,952,000 Stockholders' Equity: Accumulated Deficit $ (91,816,655 ) $ 9,477,880 $ (82,338,775 ) The impact from adopting the new revenue recognition guidance on the Company’s Condensed Consolidated Balance Sheet for the six months ending June 30, 2018 was as follows: As ‎ Reported Previous ‎ Accounting ‎ Guidance Impact from ‎ Adopting New ‎ Revenue ‎ Guidance Liabilities: Deferred Revenue $ 2,723,000 $ 13,341,100 $ (10,618,100 ) Stockholders' Equity: Accumulated Deficit $ (87,498,357 ) $ (98,116,457 ) $ 10,618,100 The impact from adopting the new revenue recognition guidance on the Company’s Condensed Consolidated Statement of Operations and Comprehensive Loss for the three and six months ended June 30, 2018 was as follows: Three Months Ended Six Months Ended As ‎ Reported Previous ‎ Accounting ‎ Guidance Impact from ‎ Adopting ‎ New Revenue ‎ Guidance As ‎ Reported Previous ‎ Accounting ‎ Guidance Impact from ‎ Adopting New ‎ Revenue ‎ Guidance Collaboration Revenue $ 242,012 $ - $ 242,012 $ 1,338,020 $ - $ 1,338,020 Operating Loss Before Other Expenses (2,798,318 ) (3,040,330 ) 242,012 (5,177,367 ) (6,515,387 ) 1,338,020 Net Loss (2,780,255 ) (3,022,267 ) 242,012 (5,159,582 ) (6,497,602 ) 1,338,020 Comprehensive Loss $ (2,778,249 ) $ (3,020,261 ) $ 242,012 $ (5,156,342 ) $ (6,494,362 ) $ 1,338,020 Under this new guidance, the Company recognizes revenue when its customer obtains control of promised services, in an amount that reflects the consideration which the Company expects to receive in exchange for those services. To determine whether arrangements are within the scope of this new guidance, the Company performs the following five steps: (i) identifies the contract with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when (or as) the Company satisfies its performance obligation. The Company applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Upon adoption of ASU No. 2014-09, the Company recognizes revenue from the transaction price applied to each single performance obligation over time as milestones are reached for each performance obligation. The Company only recognizes revenue on those milestones that are within the Company’s control and any constrained variable consideration that requires regulatory approval will only be included in the transaction price when performance is complete. The below table represents the changes in the Company’s contract assets and contract liabilities: June 30, 2018 January 1, 2018 Contract Asset: Unbilled Revenue $ - $ 116,280 Contract Liabilities: Deferred Revenue $ 2,723,000 $ 2,952,000 Three Months ‎ Ended Six Months ‎ Ended June 30, 2018 June 30, 2018 Revenue recognized in the period from: Amounts included in contract liability at the beginning of the period $ 137,000 $ 229,000 In addition, the Company may receive government grant funds for specified ocular therapeutic research activities. Revenue under these grants will be recorded when the Company performs the activities specified by the terms of each grant and is entitled to the funds.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases see On January 26, 2017, the FASB issued ASU No. 2017-04, Intangibles Goodwill and Other In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The computation of Net Loss per Common Share – Basic and Diluted, is based on the weighted-average number of shares outstanding of Common Stock. In computing diluted loss per share, no effect has been given to the shares of common stock issuable upon the conversion or exercise of the following dilutive securities, as the Company’s net loss would make the effect anti-dilutive. June 30, 2018 (unaudited) June 30, 2017 (unaudited) Common Stock Warrants 42,255,336 9,519,403 Employee Stock Options 2,106,035 1,842,255 Preferred Stock 12,787,500 400,000 Total Shares of Common Stock Issuable 57,148,871 11,761,658
Schedule Of Cummulative effect Of Revenue Recognition To Condensed Balance Sheet	The cumulative effect of initially applying the new revenue recognition guidance to the Company’s Condensed Consolidated Balance Sheet on January 1, 2018 was as follows: Balance as of ‎ December 31, ‎ 2017 Cumulative Impact ‎ from Adopting New ‎ Revenue Guidance Balance as of ‎ January 1, 2018 Assets: Unbilled Revenue $ - $ 116,280 $ 116,280 Liabilities: Deferred Revenue 12,313,600 (9,361,600 ) 2,952,000 Stockholders' Equity: Accumulated Deficit $ (91,816,655 ) $ 9,477,880 $ (82,338,775 )
Schedule Of Impact From Adopting The New Revenue Recognition Guidance On The Condensed Financial Statements	The impact from adopting the new revenue recognition guidance on the Company’s Condensed Consolidated Balance Sheet for the six months ending June 30, 2018 was as follows: As ‎ Reported Previous ‎ Accounting ‎ Guidance Impact from ‎ Adopting New ‎ Revenue ‎ Guidance Liabilities: Deferred Revenue $ 2,723,000 $ 13,341,100 $ (10,618,100 ) Stockholders' Equity: Accumulated Deficit $ (87,498,357 ) $ (98,116,457 ) $ 10,618,100 The impact from adopting the new revenue recognition guidance on the Company’s Condensed Consolidated Statement of Operations and Comprehensive Loss for the three and six months ended June 30, 2018 was as follows: Three Months Ended Six Months Ended As ‎ Reported Previous ‎ Accounting ‎ Guidance Impact from ‎ Adopting ‎ New Revenue ‎ Guidance As ‎ Reported Previous ‎ Accounting ‎ Guidance Impact from ‎ Adopting New ‎ Revenue ‎ Guidance Collaboration Revenue $ 242,012 $ - $ 242,012 $ 1,338,020 $ - $ 1,338,020 Operating Loss Before Other Expenses (2,798,318 ) (3,040,330 ) 242,012 (5,177,367 ) (6,515,387 ) 1,338,020 Net Loss (2,780,255 ) (3,022,267 ) 242,012 (5,159,582 ) (6,497,602 ) 1,338,020 Comprehensive Loss $ (2,778,249 ) $ (3,020,261 ) $ 242,012 $ (5,156,342 ) $ (6,494,362 ) $ 1,338,020
Contract with Customer, Asset and Liability	The below table represents the changes in the Company’s contract assets and contract liabilities: June 30, 2018 January 1, 2018 Contract Asset: Unbilled Revenue $ - $ 116,280 Contract Liabilities: Deferred Revenue $ 2,723,000 $ 2,952,000 Three Months ‎ Ended Six Months ‎ Ended June 30, 2018 June 30, 2018 Revenue recognized in the period from: Amounts included in contract liability at the beginning of the period $ 137,000 $ 229,000

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment at June 30, 2018 (unaudited) and December 31, 2017 consists of the following: Estimated Useful Life (Years) June 30, 2018 December 31, 2017 Laboratory Equipment 3 $ 42,576 $ 42,576 Office Furniture 5 14,430 14,430 Leasehold Improvements 2 22,569 22,569 Total Property and Equipment, Gross 79,575 79,575 Less: Accumulated Depreciation 39,756 23,824 Total Property and Equipment, Net $ 39,819 $ 55,751

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2018
Accrued Liabilities [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	June 30, 2018 (unaudited) December 31, 2017 Payroll and Benefits $ 564,977 $ 788,551 Clinical Trials 304,530 807,322 Professional Fees 153,334 149,273 Consulting 10,796 57,487 Short-Term Portion of Capital Lease Obligation 8,035 11,214 Total Accrued Expenses $ 1,041,672 $ 1,813,847

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2018
Warrants [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	At June 30, 2018, the following warrants were outstanding: Number of Awards Weighted Average Exercise Price Weighted Average Remaining Term in Years Outstanding at December 31, 2017 9,455,961 $ 3.26 4.23 Issued 35,156,250 0.32 4.80 Exercised (2,356,875 ) 0.32 4.80 Outstanding at June 30, 2018 42,255,336 $ 0.98 4.56

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	6 Months Ended
	Jun. 30, 2018
Share Based Compensation Option And Incentive Plan [Abstract]
Share-based Compensation, Stock Options, Activity [Table Text Block]	The following is a summary of stock option activity for the six months ended June 30, 2018: Number of Options Weighted- Average Exercise Price Weighted-Average Contractual Life (In Years) Outstanding at December 31, 2017 1,893,003 $ 2.49 5.40 Granted 275,500 0.57 9.65 Forfeited (1,500 ) 0.83 Expired (60,968 ) 0.80 Outstanding at June 30, 2018 2,106,035 $ 2.29 4.66 Exercisable at June 30, 2018 1,429,484 $ 2.65 3.95 Vested and Expected to Vest at June 30, 2018 1,429,484 $ 2.65 3.95
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	For the six months ended June 30, 2018 and 2017, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions: 2018 2017 Risk-Free Interest Rate 1.82% 1.82% Expected Life 7.00 years 7.29 years Expected Volatility 159% 172% Expected Dividend Yield 0% 0%
Employee and Non Employee Service Share Based Compensation Allocation off Recognized Period Costs [Table Text Block]	The total stock-based compensation expense for employees and non-employees is included in the accompanying Condensed Consolidated Statements of Operations and as follows: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Research and Development $ 49,897 $ 62,242 $ 106,975 $ 107,994 General and Administrative 95,412 172,998 183,881 404,147 $ 145,309 $ 235,240 $ 290,856 $ 512,141

Organization, Business (Details

Organization, Business (Details Textual) - USD ($)	Jun. 30, 2018	Jan. 02, 2018	Dec. 31, 2017	May 06, 2016
Subsidiary, Sale of Stock [Line Items]
Common Stock, Shares, Outstanding	42,382,880		17,257,255
Cash and Cash Equivalents, at Carrying Value	$ 12,604,803		$ 7,806,029
Retained Earnings (Accumulated Deficit)	$ (87,498,357)	$ (82,338,775)	$ (91,816,655)
Capital Units, Authorized	100,000,000	100,000,000	100,000,000	100,000,000
Series C Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred Stock, Shares Outstanding	4,092

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Details) - shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	57,148,871	11,761,658
Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	42,255,336	9,519,403
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,787,500	400,000
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,106,035	1,842,255

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Details 1) - USD ($)	Jun. 30, 2018	Jan. 02, 2018	Dec. 31, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unbilled Revenue		$ 116,280	$ 0
Deferred Revenue	$ 2,723,000	2,952,000	12,313,600
Accumulated Deficit	$ (87,498,357)	(82,338,775)	$ (91,816,655)
Cumulative Impact from Adopting New Revenue Guidance [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unbilled Revenue		116,280
Deferred Revenue		(9,361,600)
Accumulated Deficit		$ 9,477,880

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Details 2) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Jan. 02, 2018	Dec. 31, 2017
Liabilities:
Deferred Revenue	$ 2,723,000		$ 2,723,000		$ 2,952,000	$ 12,313,600
Stockholders' Equity:
Accumulated Deficit	(87,498,357)		(87,498,357)		$ (82,338,775)	$ (91,816,655)
Collaboration Revenue	242,012	$ 148,290	1,338,020	$ 332,822
Operating Loss Before Other Expenses	(2,798,318)		(5,177,367)
Net Loss	(2,780,255)	(3,326,863)	(5,159,582)	(6,246,517)
Comprehensive Loss	(2,778,249)	$ (3,324,007)	(5,156,342)	$ (6,243,596)
Previous Accounting Guidances [Member]
Liabilities:
Deferred Revenue	13,341,100		13,341,100
Stockholders' Equity:
Accumulated Deficit	(98,116,457)		(98,116,457)
Collaboration Revenue	0		0
Operating Loss Before Other Expenses	(3,040,330)		(6,515,387)
Net Loss	(3,022,267)		(6,497,602)
Comprehensive Loss	(3,020,261)		(6,494,362)
Adopting New Revenue Guidance [Member]
Liabilities:
Deferred Revenue	(10,618,100)		(10,618,100)
Stockholders' Equity:
Accumulated Deficit	10,618,100		10,618,100
Collaboration Revenue	242,012		1,338,020
Operating Loss Before Other Expenses	242,012		1,338,020
Net Loss	242,012		1,338,020
Comprehensive Loss	$ 242,012		$ 1,338,020

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details 3) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2017
Contract with Customer, Liability [Abstract]
Contract with Customer, Liability, Revenue Recognized	$ 137,000	$ 229,000
Deferred Revenue [Member]
Contract with Customer, Liability [Abstract]
Contract with Customer, Liability	2,723,000	2,723,000	$ 2,952,000
Unbilled Revenues [Member]
Contract with Customer, Asset, Net [Abstract]
Contract with Customer, Asset, Net	$ 0	$ 0	$ 116,280

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details Textual) - USD ($)	Jul. 09, 2015	Feb. 21, 2017	Jun. 30, 2018	Jan. 02, 2018	Dec. 31, 2017
Money Market Funds Fair Value			$ 0		$ 750,965
Contingent Consideration Funds Fair Value			1,210,000		$ 1,210,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			$ 3,912,314
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets				$ 9,500,000
New Valeant Agreement [Member]
Revenue Recognition, Milestone Method, Description		Company is eligible to receive milestone payments totaling up to approximately $99.0 million, upon and subject to the achievement of certain specified developmental and commercial progress of the EGP-437 Product for the New Field.
Proceeds From Upfront Payment	$ 1,000,000	$ 4,000,000
Revenue Recognition, Milestone Method, Revenue Recognized	32,500,000	99,000,000
Revenue Recognition Milestone Payments	$ 5,100,000	$ 3,400,000

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 79,575	$ 79,575
Less: Accumulated Depreciation	39,756	23,824
Property, Plant and Equipment, Net	39,819	55,751
Laboratory Equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 42,576	42,576
Property, Plant and Equipment, Useful Life	3 years
Office Furniture
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 14,430	14,430
Property, Plant and Equipment, Useful Life	5 years
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 22,569	$ 22,569
Property, Plant and Equipment, Useful Life	2 years

Property and Equipment (Detai31

Property and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Property, Plant and Equipment [Line Items]
Depreciation	$ 7,966	$ 4,536	$ 15,932	$ 9,072

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Accrued Expenses [Line Items]
Payroll and Benefits	$ 564,977	$ 788,551
Clinical Trials	304,530	807,322
Professional Fees	153,334	149,273
Consulting	10,796	57,487
Short-Term Portion of Capital Lease Obligation	8,035	11,214
Total Accrued Expenses	$ 1,041,672	$ 1,813,847

Capital Stock (Details Textual)

Capital Stock (Details Textual) - USD ($)	Jun. 14, 2017	Apr. 18, 2018	Apr. 17, 2018	Jun. 15, 2017	May 24, 2016	Mar. 31, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Class of Stock [Line Items]
Common Stock, Shares Authorized							100,000,000		100,000,000
Common Stock, Par or Stated Value Per Share							$ 0.01		$ 0.01
Common Stock, Shares, Outstanding							42,382,880		17,257,255
Preferred Stock, Shares Authorized							9,994,184		9,995,828
Preferred Stock, Par or Stated Value Per Share							$ 0.01		$ 0.01
Convertible Preferred Stock, Shares Issued upon Conversion	1,330,000		20,426,250
Proceeds from Issuance or Sale of Equity	$ 8,800,000		$ 10,100,000
Sale of Stock, Number of Shares Issued in Transaction					1,319,289
Sale of Stock, Consideration Received on Transaction					$ 3,285,798
Proceeds from Issuance of Common Stock						$ 1,800,000	$ 10,108,762	$ 10,589,183
Issuance of Common Stock, Description	the Company is restricted from issuing any shares pursuant to the ATM Agreement for a period of twenty-four months following the closing date of the offering. However, this restriction is suspended for any sale of shares of Common Stock under the ATM Agreement that is above $3.00 per share.
Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.50		$ 0.32
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	6,666,667		35,156,250
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	5,336,667		14,730,000			642,150
Convertible Preferred Stock, Shares Issued upon Conversion	450,000	3,263,750	4,375,000	880,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share							$ 0.01		$ 0.01
Preferred Stock, Shares Issued							0		0
Preferred Stock, Shares Outstanding							0		0
Common Stock, Other Shares, Outstanding							0
Preferred Stock Designated Shares							3,750		3,750
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share							$ 0.01		$ 0.01
Stock Issued During Period, Shares, New Issues	1,995
Preferred Stock, Shares Issued							0		600
Preferred Stock, Shares Outstanding							0		600
Conversion of Stock, Shares Converted	675			1,320
Common Stock, Other Shares, Outstanding							0
Preferred Stock Designated Shares							10,000		10,000
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues			6,536.4				6,536
Preferred Stock, Shares Issued							4,092
Preferred Stock, Shares Outstanding							4,092
Conversion of Stock, Shares Converted		1,044.4	1,400
Common Stock, Other Shares, Outstanding							12,787,500
Preferred Stock Designated Shares							10,000		10,000

Warrants (Details)

Warrants (Details) - Warrant [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Awards, Outstanding	9,455,961
Number of Awards, Issued	35,156,250
Number of Awards, Exercised	(2,356,875)
Number of Awards, Outstanding	42,255,336	9,455,961
Weighted Average Exercise Price, Outstanding	$ 3.26
Weighted Average Exercise Price, Issued	0.32
Weighted Average Exercise Price, Exercised	0.32
Weighted Average Exercise Price, Outstanding	$ 0.98	$ 3.26
Weighted Average Remaining Term in Years, Outstanding	4 years 6 months 22 days	4 years 2 months 23 days
Weighted Average Remaining Term in Years, Issued	4 years 9 months 18 days
Weighted Average Remaining Term in Years, Exercised	4 years 9 months 18 days

Equity Incentive Plan (Details)

Equity Incentive Plan (Details) - Equity Incentive Plan 2014 [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding beginning of year	1,893,003
Number of Options, Granted	275,500
Number of Options, Forfeited	(1,500)
Number of Options, Expired	(60,968)
Number of Options, Outstanding at end of period	2,106,035	1,893,003
Number of Options, Exercisable at end of period	1,429,484
Number of Options, Vested and expected to vest at end of period	1,429,484
Weighted- Average Exercise Price, Outstanding at beginning of year	$ 2.49
Weighted- Average Exercise Price, Granted	0.57
Weighted- Average Exercise Price, Forfeited	0.83
Weighted- Average Exercise Price, Expired	0.80
Weighted- Average Exercise Price, Outstanding at end of period	2.29	$ 2.49
Weighted- Average Exercise Price, Exercisable at end of period	2.65
Weighted- Average Exercise Price, Vested and expected to vest at end of period	$ 2.65
Weighted-Average Contractual Life (In Years), Outstanding	4 years 7 months 28 days	5 years 4 months 24 days
Weighted-Average Contractual Life (In Years), Granted	9 years 7 months 24 days
Weighted-Average Contractual Life (In Years), Exercisable at end of period	3 years 11 months 12 days
Weighted-Average Contractual Life (In Years), Vested and expected to vest at end of period	3 years 11 months 12 days

Equity Incentive Plan (Details

Equity Incentive Plan (Details 1)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Risk-Free Interest Rate	1.82%	1.82%
Expected Life	7 years	7 years 3 months 14 days
Expected Volatility	159.00%	172.00%
Expected Dividend Yield	0.00%	0.00%

Equity Incentive Plan (Detail37

Equity Incentive Plan (Details 2) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 145,309	$ 235,240	$ 290,856	$ 512,141
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	49,897	62,242	106,975	107,994
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 95,412	$ 172,998	$ 183,881	$ 404,147

Equity Incentive Plan (Detail38

Equity Incentive Plan (Details Textual) - USD ($)	1 Months Ended	6 Months Ended
	Feb. 28, 2018	Jun. 30, 2018	Jun. 30, 2017	Mar. 21, 2018	Jan. 31, 2018	Dec. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 805,000	$ 1,295,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		1 year 6 months 25 days	2 years 1 month 13 days
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Intrinsic Value		$ 0	$ 326,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	In general, options granted under the 2014 Plan vest with respect to one-third of the underlying shares on the one-year anniversary of the grant date and the remainder ratably over a 24-month period.
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						891,222
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		0	78,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 151,000	$ 530,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0.57	$ 1.47
Share-based Compensation Arrangement by Share-based Payment Award, Description		Incentive stock options may be granted to any officer or employee at an exercise price per share of not less than the fair value per common share on the date of the grant (not less than 110% of fair value in the case of holders of more than 10% of the Company’s voting stock) and with a term not to exceed ten years from the date of the grant (five years for incentive stock options granted to holders of more than 10% of the Company’s voting stock).
Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Granted in Period Fair Value			$ 158,000
Sixteen Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	275,000
One Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant				500
Equity Incentive Plan 2014 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		2,040,123
ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		117,090
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		170,567
2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		192,411
Excess Stock, Shares Authorized					350,000

Commitments and Contingencies (

Commitments and Contingencies (Details Textual)	Jul. 09, 2015USD ($)	Sep. 12, 2013USD ($)	Feb. 21, 2017USD ($)	Jun. 17, 2016USD ($)	Feb. 15, 1999USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Jun. 30, 2018ft²	Jul. 06, 2016ft²
Commitments and Contingencies [Line Items]
Area of Land | ft²									2,300
Lease Expiration Period					12 years
Payment of annual fee		$ 30,000
License [Member]
Commitments and Contingencies [Line Items]
Cost of Goods and Services Sold		$ 50,000		$ 15,000	$ 12,500
Subsequent Event [Member]
Commitments and Contingencies [Line Items]
Operating Leases, Future Minimum Payments Due						$ 144,000	$ 86,000
Minimum [Member] | License [Member]
Commitments and Contingencies [Line Items]
Cost of Goods and Services Sold				5,000
Maximum [Member] | License [Member]
Commitments and Contingencies [Line Items]
Cost of Goods and Services Sold				$ 20,000
New Valeant Agreement [Member]
Commitments and Contingencies [Line Items]
Revenue Recognition, Milestone Method, Description			the Company is eligible to receive milestone payments totaling up to approximately $99.0 million, upon and subject to the achievement of certain specified developmental and commercial progress of the EGP-437 Product for the New Field.
Proceeds From Upfront Payment			$ 4,000,000
Revenue Recognition, Milestone Method, Revenue Recognized			$ 99,000,000
Licensor [Member]
Commitments and Contingencies [Line Items]
Area of Land | ft²								4,516
Valeant Pharmaceuticals International Inc [Member] | Licensing Agreements [Member]
Commitments and Contingencies [Line Items]
Payments to Acquire Intangible Assets	$ 1,000,000
Proceeds from Sale of Intangible Assets	$ 32,500,000

Subsequent Events (Details Text

Subsequent Events (Details Textual) - shares	Jul. 10, 2018	Jun. 30, 2018	Dec. 31, 2017
Subsequent Event [Line Items]
Common Stock, Shares Authorized		100,000,000	100,000,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Common Stock, Shares Authorized	120,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	6,000,000